

Cerebral amyloid angioathy: vascular imaging and fluid biomarkers of amyloid deposition

<https://www.neurodegenerationresearch.eu/survey/cerebral-amyloid-angioathy-vascular-imaging-and-fluid-biomarkers-of-amyloid-deposition/>

Title of study

Cerebral amyloid angioathy: vascular imaging and fluid biomarkers of amyloid deposition

Acronym for cohort

CAVIA

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Marcel

Name of Principal Investigator - Last name

Verbeek

Address of institution -Institution

Radboudumc, Department of Neurology - 830 TML

Address of institution - Street address

PO Box 9101

Address of institution - City

Nijmegen

Address of institution - Postcode

6500 HB

Country

Netherlands

Website

www.caviaproject.nl

Contact email

Funding source

ZonMW

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To identify novel biomarkers for Cerebral Amyloid Angiopathy, including body fluid (cerebrospinal fluid, blood) and imaging (MRI) biomarkers.

Q2b. What distinguishes this case-control study from other studies?

The focus on the identification of biomarkers for Cerebral Amyloid Angiopathy (CAA) is unique, but is very relevant since CAA occurs at high frequency in brains of elderly and AD patients and contributes to cognitive impairment.

Q3a. i) Number of publications that involve use of your cohort to date

4

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

Description of novel body fluid and imaging biomarkers for hereditary and sporadic CAA

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years
From:**

50

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

For CAA patients: Clinical diagnosis based on "Boston criteria". For memory clinic patients: no specific inclusion criteria, apart from availability of both CSF and MRI (T2* or SWI)

Q4c. Study criteria: what are the exclusion criteria?

No MRI or CSF available

Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1-1,000

Q5b. What is the expected number of control participants?

200-500

Q6a. Please describe what measures are used to characterise participants

MRI and clinical / neurological examinations

Q6b. Are there additional measures for participants with the clinical disorder?

Boston criteria for CAA

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If YES please specify

Q7. What is the study design?

Retrospective cohort| Cross sectional survey

Q8. Are your cases matched by

Age| Sex

Q9a. Does your study includes a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe

cases without history of neurological disease, but with CSF & MRI

Q10a. Is data collection for this study

Data collection ongoing| Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Are data collected

Through links to medical records

Q12. Is there a system in place to enable re-contact with patients for future studies?

No

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

Q13a. Please give information on data stored in a database (2)

Database is web-based

% Available

Q13a. Please give information on data stored in a database (3)

No

% Available

Q13a. Please give information on data stored in a database (4)

No

% Available

Q13a. Please give information on data stored in a database (5)

No

% Available

Please specify language used

% Available

Q13b. Please give information on how data is held as individual records

Data is web-based

% Available

Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Access through collaboration with PI only| Local/ regional access| National access| International access| Access to industry| Access for pilot studies permitted

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below

Living donors: blood| Living donors: cerebro-spinal fluid

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary Samples: Stabilised samples (frozen or fixed)

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Types:

Case Control Studies

Member States:

Netherlands

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A